TaiGen Biotechnology Company, Ltd. and R-Pharm Group announced the completion of patient enrollment for phase III clinical trials of Taigexyn® (nemonoxacin) for the treatment of community-acquired pneumonia in Russia.
Multicenter, randomized, active-controlled Phase III clinical trials are conducted to compare the efficacy and safety of intravenous and oral forms of Taigexyn® and Tavanic® (levofloxacin) in adult patients with community-acquired pneumonia. Once the trials and data analysis are complete, R-Pharm will apply for the registration of new medicinal product.
Dr. Ming-Chu Hsu, the President and CEO of TaiGen, said, “We want to congratulate our partners in R-Pharm with successful completion of yet another stage. This is a key event in the development of Taigexyn®, because the Phase III clinical trials are for the first time conducted outside China.”
Vasily Ignatiev, the Director General of R-Pharm JSC, said, “The clinical trials should confirm the high efficacy profile of the medicine. This will enable us to launch, in the near future, a safe and effective drug in the Russian market.”